Skip to main content

Table 1 Demographic data and preexisting comorbidities in 239 critically ill patients with COVID-19

From: Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China

Characteristics All patients (n = 239) Non-survivors (n = 147) Survivors (n = 92) p value, survivors vs non-survivors
Age, mean ± SD, years 62.5 ± 13.3 65.7 ± 12.2 57.5 ± 13.5 < 0.001
Age ≥ 65 years 112 (46.9%) 82 (55.8%) 30 (32.6%) < 0.001
Male 143 (59.8%) 90 (61.2%) 53 (57.6%) 0.337
APACHE II, median [IQR]a 15 [13–17] 15 [13–17] 13 [11–15] 0.006
SOFA scorea 6 [5–7] 6 [5–7] 5 [5–6] 0.0163
Preexisting comorbidities
 Hypertension 105 (43.9%) 64 (43.5%) 41 (44.6%) 0.491
 Chronic cardiac disease 35 (14.6%) 21 (14.3%) 14 (15.2%) 0.492
 Chronic pulmonary disease 12 (5.0%) 9 (6.1%) 3 (3.3%) 0.253
 Cerebrovascular disease 13 (5.4%) 9 (6.1%) 4 (4.3%) 0.392
 Chronic liver disease 20 (8.4%) 13 (9.4%) 7 (8.4%) 0.511
 Malignancy 13 (5.4%) 11 (7.5%) 2 (2.2%) 0.066
 Diabetes 44 (18.4%) 24 (17.7%) 18 (19.6%) 0.420
  1. COVID-19 coronavirus disease 2019, SD standard deviation, APACHE II Acute Physiology and Chronic Health Evaluation II, IQR interquartile range
  2. Data were expressed as count (%) unless otherwise
  3. aAPACHE II scores at ICU admission were available in 165 patients, because arterial blood gas analysis was conducted in 101 non-survivors and 64 survivors